SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Political uncertainty ahead of the midterm elections and debate over the Iran conflict dominate discussion, with traders linking war and cost-of-living concerns to market pressure and DJTs decline. Bearish views prevail, though some speculate a peace deal or Republican win could improve sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody for menopausal hot flashes: traders are discussing its positive Phase 2 results and additional conference data while watching for longer-term durability results and clarity on a Phase 3 path. Bulls view the program as validation of AbCelleras pipeline, while skeptics say the latest presentation added little beyond known results and want more concrete clinical updates.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks to acquire Lumentum have driven attention, with traders worried the large deal could require substantial share dilution or debt and weigh on Marvell. Some see strategic value in combining Marvells AI networking chips with Lumentums optical technology, but the talks remain unconfirmed and the market reaction has been sharply negative.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas negative S&P outlook, tied to heavy AI infrastructure spending and uncertainty about free cash flow, is driving concern alongside fears that planned stock sales could dilute shareholders. Traders debate whether strong advertising growth and potential AI monetization can justify the investment, with some viewing the selloff as a buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with hopes for a winter-weather rebound. Traders disagree over whether colder forecasts and tighter storage could spark a bounce, while others point to mild-weather expectations, ample supply, and the ETFs leverage and futures-roll decay as risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking 

Equity

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 


J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down

JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot 

The U.S. Food and Drug Administration approved Weltruza as an extended-release injectable suspension for adults with schizophrenia.

J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?

JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.

FDA Approves Teva's Once-Monthly Injectable Olanzapine

(RTTNews) - Friday, Teva Pharmaceuticals (TEVA) announced that the U.S. FDA has approved WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia...

Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being developed for pediatric patients with Tourette syndrome...

Here's Why You Should Add URGN Stock to Your Portfolio Now

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

Teva's Shares Now Trade Directly on the NYSE  Here's What Else Changed

Teva Pharmaceutical Industries had a busy week that included a major debt refinancing, a NYSE trading shift and analyst activity.read more...

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd.

Neutral Sentiment

<ul class="summary-bullets"><li>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A.&nbsp;</li><li>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale.</li><li>The week marked an extension of a quieter stretch in biotech dealmaking after larger deals in the first half of 2026.</li></ul><p>U.S.-listed drugmakers continued to prefer asset licensing and bankruptcy purchases of drug candidates this week rather than large full-company acquisitions, marking a quieter stretch compared with earlier in 2026, when multi-billion-dollar buyouts of U.S. biotechs dominated.</p><p>This week, rare-disease enzyme therapies and late-stage neuroscience assets drew the most capital as BioMarin and Teva sought to strengthen their positions in certain clinical areas.</p><h2 class="st-heading-2">BioMarin Licenses Long-Acting Fabry Therapy</h2><p>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease, a rare disorder that causes a fatty substance to build up inside cells and blood vessels.</p><p>BioMarin is paying $70 million upfront. The Korean partners are jointly eligible for up to $405 million in further milestones plus tiered royalties. The candidate is in an early-stage trial and is designed for subcutaneous dosing. BioMarin will lead subsequent global development and commercialization outside Korea.</p><p>The licensing deal reflects BioMarin’s efforts to build a pipeline aimed at Fabry, after its acquisition of Amicus Therapeutics was completed earlier this year. The previous deal brought Amicus’s Galafold, approved for Fabry disease, under BioMarin’s fold.</p><p><a class="mention" data-mention="$BMRN" data-symbol-id="BMRN" href="https://stocktwits.com/symbol/BMRN" target="_blank">BMRN stock</a> gained about 5% this week.</p><h2 class="st-heading-2">Teva Acquires BioXcel Neuroscience Assets</h2><p>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale. The deal, announced earlier this week, includes worldwide rights to BXCL501, an investigational therapy under FDA review for potential at-home treatment of agitation associated with schizophrenia or bipolar disorder, and the approved hospital product IGALMI. Teva paid $57.5 million upfront and could owe up to $67.5 million in contingent payments tied to regulatory timing and sales milestones.</p><p>The purchase supports Teva’s pivot toward innovative neuroscience assets. Earlier this year, the company also acquired Emalex Biosciences for $700 million upfront to gain its neuroscience candidate ecopipam for the treatment of Tourette syndrome.</p><p>TEVA stock added about 7% this week.</p><h2 class="st-heading-2">The Shift In Dealmaking Approach</h2><p>Earlier in 2026, U.S.-listed buyers deployed substantial capital to fully acquire other U.S. biotechs. Major deals that moved markets included Vertex’s <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-soars-nearly-100-percent-on-vertex-10-billion-acquisition/cZmlGWWR7mT">acquisition</a> of Crinetics, AbbVie’s purchase of Apogee, Gilead’s buyout of Arcellx, and others that together pushed total U.S. biotech <a href="https://stocktwits.com/news-articles/markets/equity/gilead-merck-eli-lilly-lead-106-billion-takeover-wave-in-2026/cZ0FblYRezX">merger and acquisition</a> value well above prior-year levels by the end of the third quarter. Capital also flowed into large licensing packages, particularly for China-originated assets showing potential in immune-system-mediated diseases, cancer, or obesity.</p><p>On Stocktwits, retail sentiment around BMRN was 'neutral' at the time of writing, while sentiment around TEVA was 'neutral.'&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/stocktwits-zero-to-sixty-rivian-beats-q3-estimates-on-r2-strength-and-raises-guidance-tesla-expands-robotaxi-fleet-and-ford-advances-low-cost-ev-plans/cZUKK8sR9cB">Stocktwits Zero To Sixty: Rivian Raises Delivery Guidance On R2 Demand, Tesla Expands Robotaxi Fleet, And Ford Advances Low-Cost EV Plans</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Assortment of colorful tablets, capsules, and softgel supplements arranged in a clean repeating pattern against a minimal background. Source: Getty Images

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Biomarin Pharmaceutical Inc. - Registered Shares

Teva- Pharmaceutical Industries Ltd. - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$42.09
Prev Close	$41.47
Open	$41.17
Dividend Yield	0.00%
50-Day Moving Average	$39.09
Beta	0.80
Avg. Volume	5.25M
PE Ratio	70.17

52-Week High	$42.59
52-Week Low	$20.11
Market Capitalization	$49.05B
EPS (Annual)	$1.21
Price to Book	6.32
Revenue Per Employee	$519,492.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

TEVA Fundamentals